Burning Rock Biotech (NASDAQ:BNR – Get Free Report) is anticipated to issue its Q3 2026 resultson Tuesday, November 17th. Analysts expect Burning Rock Biotech to announce earnings of ($0.3412) per share and revenue of $19.20 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.
Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last announced its quarterly earnings results on Thursday, September 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The firm had revenue of $19.84 million for the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 12.98% and a negative net margin of 13.60%.
Burning Rock Biotech Trading Down 7.7%
NASDAQ BNR opened at $12.39 on Tuesday. The company has a 50 day moving average of $13.51 and a 200-day moving average of $15.95. The firm has a market cap of $130.34 million, a price-to-earnings ratio of -14.24 and a beta of 1.50. Burning Rock Biotech has a 1-year low of $6.79 and a 1-year high of $41.72.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on BNR shares. Wall Street Zen raised shares of Burning Rock Biotech to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings raised Burning Rock Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Read Our Latest Report on Burning Rock Biotech
About Burning Rock Biotech
Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy.
Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies.
Featured Stories
- Five stocks we like better than Burning Rock Biotech
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
